Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Rackspace Technology Inc. Common Stock (RXT) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

Rackspace Technology Inc. Common StockTrade
Travere Therapeutics Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

Rackspace Technology Inc. Common Stock vs Travere Therapeutics Inc. Common Stock — how do they compare? Rackspace Technology Inc. Common Stock trades at $3.1 (market cap $925.19M), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 5.3× Rackspace Technology Inc. Common Stock's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Rackspace Technology Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Rackspace Technology Inc. Common Stock for 0 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.

RXTTVTX
Market Cap
$925.19M$4.88B
Volume
2,631,3641,668,577
Sector
TechnologyHealth
52-Week High
$7.53$67.52
52-Week Low
$0.41$26.79
Typical Hold Time
0 Days0 Days
Enterprise Value
$4.09B$5.01B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Rackspace Technology Inc. Common Stock

No Aura AI signal available yet.

Travere Therapeutics Inc. Common Stock

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

RXT
100% Buy0% Sell
Avg holding period · 0 Days
TVTX
100% Buy0% Sell
Avg holding period · 0 Days

About Rackspace Technology Inc. Common Stock

Rackspace Technology, Inc. provides managed multicloud and hybrid cloud services, helping organizations design, operate, and support workloads across AWS, Microsoft Azure, Google Cloud, and private infrastructure.

Read more on RXT →

About Travere Therapeutics Inc. Common Stock

Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.

Read more on TVTX →